Dual immunotherapy treatment before surgery in melanoma patients
Source: The Medical Independent, July 2024
Neoadjuvant immunotherapy given for stage III melanoma, followed by adjuvant therapy only if there is not a deep response to treatment, promises better outcomes for patients than the current standard of care, which is adjuvant immunotherapy alone.
This is according to data from the phase 3 NADINA trial presented at the 2024 ASCO Annual Meeting.
Recent evidence from phase 1 and phase 2 clinical trials has suggested that adding immunotherapy before surgery (neoadjuvant therapy) may help improve patient outcomes.